Category: News
-
Seamflow secures $4.5m to deploy AI for testing and certification bottlenecks
London-based AI startup raises seed funding to tackle certification delays in medical devices and industrial sectors.
-
RevealDx wins FDA clearance for lung nodule assessment software
New AI software aims to help radiologists assess lung nodule cancer risk and improve early detection.
-
Inside Immunai’s plan to map the entire immune system
Immunai CEO Noam Solomon details four pivotal studies shaping the future of immunology and oncology research, as part of the ‘Grand Collaboration’.
-
CAR T enters a new era of in vivo reprogramming of T cells
Vyriad’s Luke Russell explores the technical and economic promise of in vivo CAR T-cell therapies.
-
Rapid Nexus study challenges neuropathy as the point of no return
New peer-reviewed research indicates nerve function is key to healing tissue once considered unsalvageable.
-
Genesipre’s rare disease therapy gets orphan drug status in the US and Europe
The gene therapy is being developed to treat a rare pediatric metabolic disease, methylmalonic acidemia (MMA).
-
Boehringer picks AI imaging tech as co-primary endpoint for IPF trial
Brainomix’s e-Lung AI will provide quantitative imaging biomarkers as a co-primary endpoint in Boehringer Ingelheim’s Phase III DROP-FPF study.
-
VCU researchers win $1.8 million US DoD grant for cancer therapy
The US Department of Defense (DoD) grant funds engineered NK cell therapy for resistant prostate cancer.
-
Becton Dickinson and ten23 partner on wearable injector supply
Partnership will support the supply for Becton, Dickinson and Company’s self-administered therapies with a ready-to-use, scalable platform.
-
Stereotaxis MAGiC catheter cleared by FDA for robotic heart ablation
The US FDA approves Stereotaxis’ robotic magnetic navigation catheter for complex cardiac arrhythmia procedures.
-
Canopy raises $22 million for healthcare safety platform
The Series B funding is expected to finance the expansion of Canopy’s connected safety platform across US health systems.
-
Eisai subsidiary starts Phase III trial for Schizophrenia drug in Japan
EA Pharma initiates a pivotal study of the novel glutamate modulator, evenamide, for treatment-resistant schizophrenia in Japan.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.